Cross-Sector entity
CRPS-RISE Phase 3 trial is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is acquisition: 1 of 2 stories, with the rest divided among 1 other category. Each carries 2 original sources on average.
2 verified stories tracked
Last mentioned: Aug 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
CRPS-RISE Phase 3 trial is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is acquisition: 1 of 2 stories, with the rest divided among 1 other category. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention Ambros Therapeutics, all published on August 22, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ambros Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Cash runway into first half of 2029
Proceeds from the $150 million private placement are expected to fund a planned NDA submission and operations into the first half of 2029.
CRPS-RISE Phase 3 topline results expected
Ambros expects to report topline results from the pivotal CRPS-RISE trial evaluating neridronate in warm CRPS-1.
Merger and $150M financing announced
Werewolf Therapeutics and Ambros Therapeutics announce a definitive all-stock merger and an oversubscribed $150 million private placement.
Neridronate, an investigational CRPS-1 bisphosphonate already approved in Italy, moves into a 270-patient pivotal CRPS-RISE Phase 3 with FDA Breakthrough, Fast Track, and Orphan designations. The all-stock Werewolf-Ambros merger and oversubscribed $150 million private placement fund development through topline in 2028.
The Werewolf-Ambros merger creates a Nasdaq-listed company focused on neridronate for CRPS-1, an under-served pain indication affecting 65,000 newly diagnosed U.S. patients yearly. A $150 million financing funds a 270-patient pivotal Phase 3 trial with topline data expected in 2028.
Source: rttnews.com · Investing South Africa
